Latest news with #InducementEquityIncentivePlan
Yahoo
4 days ago
- Business
- Yahoo
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England, June 03, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 50,000 shares of KalVista common stock on June 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow on social media at @KalVista and LinkedIn. View source version on Contacts KalVista Pharmaceuticals, Inc. Investors: Ryan BakerHead, Investor Relations(617) Media: Molly CameronDirector, Corporate Communications(857)
Associated Press
5 days ago
- Business
- Associated Press
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By BioCryst Pharmaceuticals, Inc. Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. The RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn . BCRXW Contact: John Bluth +1 919 859 7910 [email protected] The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world's population sees AP journalism every day.
Yahoo
30-05-2025
- Business
- Yahoo
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif., May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 77,350 shares of GRAIL's common stock to 38 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4). The RSUs vest over an approximately four year period, with 25% of the award vesting May 31, 2026, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates. About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. For more information, visit View original content to download multimedia: SOURCE GRAIL, Inc.
Business Wire
29-05-2025
- Business
- Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company's newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian. As previously announced, Mr. Aklian joined the company on May 28, 2025. The grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, effective as of May 29, 2025, and were made as a material inducement to Mr. Aklian's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation. The inducement grants consisted of a non-statutory stock option to purchase 84,375 shares of the company's common stock and restricted stock units (RSUs) with respect to 14,063 shares of the company's common stock. The stock option has an exercise price of $21.44 per share, equal to the closing price of the company's common stock on May 29, 2025. The stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when Mr. Aklian completes 12 months of continuous service measured from his employment start date, and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon Mr. Aklian's completion of each additional month of service over the 36-month period following the first anniversary of his employment start date, subject to continued service. The RSUs vest over four years, with 25 percent of such RSUs vesting when Mr. Aklian completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon Mr. Aklian's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn, or visit our blog,
Yahoo
29-05-2025
- Business
- Yahoo
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
NEW YORK, May 29, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company's newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian. As previously announced, Mr. Aklian joined the company on May 28, 2025. The grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, effective as of May 29, 2025, and were made as a material inducement to Mr. Aklian's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation. The inducement grants consisted of a non-statutory stock option to purchase 84,375 shares of the company's common stock and restricted stock units (RSUs) with respect to 14,063 shares of the company's common stock. The stock option has an exercise price of $21.44 per share, equal to the closing price of the company's common stock on May 29, 2025. The stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when Mr. Aklian completes 12 months of continuous service measured from his employment start date, and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon Mr. Aklian's completion of each additional month of service over the 36-month period following the first anniversary of his employment start date, subject to continued service. The RSUs vest over four years, with 25 percent of such RSUs vesting when Mr. Aklian completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon Mr. Aklian's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn, or visit our blog, View source version on Contacts Investor contact: Allie Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
